GET STARTED WITH OUR PHARMACY PROVIDER

HAVE A QUESTION? GET IN TOUCH
#1 perscribed oral TRT*

Hear from your Peers

Practical peer conversations on the state of Testosterone Replacement Therapy (TRT), with a keen focus on helping men manage their TRT— not just starting it.

“Hear from your peers” is an educational video series dedicated to honest, experience-based discussions about Testosterone Replacement Therapy (TRT). Each episode dives into the real-world challenges and strategies of managing TRT—not just starting it. Hear from experts who are redefining what healthy testosterone management looks like today.

Beyond the Black Box: A New Look at TRT Safety

Dr. Martin Miner moderates a blue-chip panel of urologists—Dr. Stanton Honig, Dr. Petar Bajic, and Dr. Scott Lundy on the FDA’s removal of the Black Box Warning on adverse cardiovascular outcomes for testosterone following the TRAVERSE study. The roundtable covers new safety data, TRT options, and differences in dosing, administration, and pharmacokinetics. Clinicians will gain practical insights to confidently prescribe and manage testosterone therapy for diverse patients.

What are your peers saying?

66%patients
switched TRTs in
the past year1
73%physicians feel
that TRAVERSE will
increase TRT Rx1
55%of physicians still cite
safety as a prescribing
behavior1

Tailoring TRT for Fertility and 
Cardiometabolic Patients

MODERATOR: Dr. Martin Miner, Brown University
PANELISTS: Dr. Petar Bajic, Cleveland Clinic; Dr. Stanton Honig, Yale University; Dr. Scott Lundy, Cleveland Clinic
The panel explores clinical challenges in managing TRT for patients with fertility considerations, cardiometabolic disease, and diabetes.

Oral TRT Dosing & Lab Strategies

MODERATOR: Dr. Martin Miner, Brown University
PANELISTS: Dr. Petar Bajic, Cleveland Clinic; Dr. Stanton Honig, Yale University; Dr. Scott Lundy, Cleveland Clinic
The panel discusses dosing and differences in baseline lab strategies for diagnosis versus monitoring. The panelists discuss their approach to relevant lab tests and pharmacokinetic differences between short- and long-acting TRT.

When to Switch Your Patient’s TRT

MODERATOR: Dr. Martin Miner, Brown University
PANELISTS: Dr. Petar Bajic, Cleveland Clinic; Dr. Stanton Honig, Yale University; Dr. Scott Lundy, Cleveland Clinic
The panel discusses trends in TRT formulation switching, safety triggers such as elevated hematocrit, and strategies for individualized, patient-centered therapy.

Looking at Differing Guidelines: Does TRT Need its Own Care Pathway?

MODERATOR: Dr. Martin Miner, Brown University
PANELISTS: Dr. Petar Bajic, Cleveland Clinic; Dr. Stanton Honig, Yale University; Dr. Scott Lundy, Cleveland Clinic

The panel explores how overlapping specialty guidelines impact TRT management and the need for a standardized clinical care pathway that supports both initiation and long-term patient management.

Key Take-Aways on Removal of Black Box Warning for TRT

MODERATOR: Dr. Martin Miner, Brown University
PANELISTS: Dr. Peter Bajic, Cleveland Clinic; Dr. Stanton Honing, Yale University, Dr. Scott Lundy, Cleveland Clinic.

The panel summarizes their key takeaways on the FDA TRT label change and implications to clinical practice.

SPOTLIGHT: JATENZO Oral Testosterone Undecanoate

MODERATOR: Dr. Martin Miner, Brown UniversityPANELISTS: Dr. Peter Bajic, Cleveland Clinic; Dr. Stanton Honing, Yale University, Dr. Scott Lundy, Cleveland Clinic.

The panel discusses JATENZO, a short-acting, easy-to-titrate testosterone undecanoate. The panelists share their perspectives on its efficacy, safety profile, flexible dosing, and key points from its recent label update.

IMPORTANT SAFETY INFORMATION FOR JATENZO (testosterone undecanoate)

Indication and Limitations of Use:

JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

  • Primary hypogonadism (congenital or acquired)
  • Hypogonadotropic hypogonadism (congenital or acquired)

Safety and efficacy of JATENZO in men with “age-related hypogonadism” and in males less than 18 years old have not been established.

IMPORTANT SAFETY INFORMATION FOR JATENZO (testosterone undecanoate)

CONTRAINDICATIONS

JATENZO is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate, in women who are pregnant, or in men with a known hypersensitivity to JATENZO or its ingredients.

WARNINGS AND PRECAUTIONS

Increase in hematocrit and polycythemia. High red blood cell counts increase the risk of clots, strokes, and heart attacks.

Venous thromboembolic events (VTE). Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone replacement products like JATENZO.

Benign prostatic hyperplasia (BPH). Patients may see worsening signs and symptoms of BPH.

Prostate cancer. Patients treated with androgens may be at increased risk for prostate cancer.

Blood pressure increases. JATENZO can increase blood pressure. Monitor blood pressure periodically in men using JATENZO. Not recommended for use with uncontrolled hypertension.

Abuse. Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Testosterone abuse can lead to serious cardiovascular and psychiatric adverse reactions.

Suppression of spermatogenesis. Large doses of androgens, like JATENZO, can suppress spermatogenesis.

Hepatic adverse events. JATENZO is not known to cause liver adverse events; however, patients should be instructed to report any signs of hepatic dysfunction.

Retention of sodium and water.

Gynecomastia.

Sleep apnea. Testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.

Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy.

Risk of hypercalcemia.

ADVERSE EVENTS

The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

DRUG INTERACTIONS

JATENZO can cause changes in insulin sensitivity or glycemic control and changes in anticoagulant activity. Use of testosterone and corticosteroids concurrently may increase fluid retention. Use of prescription and nonprescription analgesic cold medications with JATENZO have been known to increase blood pressure.

To report suspected adverse reactions contact Tolmar at 1-844-4TOLMAR (486-5627) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see full Prescribing Information.

Reference

1. Data on file. The landmark SERMO survey: The State of TRT in 2024. (conducted Feb. 16 - Mar. 1, 2024). Tolmar, Inc.